HIV-positive Clinical Trial
— SMSaudeOfficial title:
Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique: A Randomized Control Trial
Mobile phone SMS are increasingly used to promote positive health behaviour with an aim to improve health outcomes. However, robust data on the efficacy of SMS on health seeking behaviour and patient outcomes in resource-limited settings is sparse. The SMSaude study aims to assess whether regular SMS-reminders improve retention on antiretroviral therapy (ART) and prevention of mother to child transmission of HIV (PMTCT) programmes in Mozambique.
Status | Completed |
Enrollment | 1352 |
Est. completion date | June 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - On ART for >15 days (for ART only) - Live in province and plan to stay for 12+ months - Have cell phone - Literate For PMTCT (in addition to above criteria): - pregnant between 8-28 weeks Exclusion Criteria: |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Mozambique | 6 Health Facilities | Matola, Xinavane, Machava and Namaacha | Maputo |
Lead Sponsor | Collaborator |
---|---|
Absolute Return for Kids | Department for International Development, United Kingdom, United States Agency for International Development (USAID), Vodacom |
Mozambique,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retention in ART care | 12 months | No | |
Secondary | Retention in PMTCT care | until 8 weeks post partum | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05135689 -
Medico-social Description of Seniors Living With HIV, Associated With a Qualitative Survey on Their Care in the Paris Region Structures
|
||
Completed |
NCT01296113 -
Chemotherapy for Lung Cancer in HIV-positive Patients
|
Phase 2 |